Lipofundin Mct/Lct

Soya-Bean Oil Refined, the active ingredient in Lipofundin MCT/LCT, is a parenteral nutrition lipid emulsion presented as an emulsion for intravenous infusion use. It provides calories and essential fatty acids for patients requiring total parenteral nutrition, such as those unable to receive enteral feeding, and supports metabolic needs during critical illness.

GNH USA supplies Lipofundin MCT/LCT as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, and ensures product quality through rigorous regulatory standards and cold‑chain logistics.

Lipofundin MCT/LCT is employed in parenteral nutrition to deliver essential fatty acids and caloric energy to patients who cannot receive enteral feeding.

Parenteral nutrition: supplies a high‑energy lipid source and essential fatty acids to support caloric requirements in total parenteral nutrition regimens. Essential fatty acid supplementation: prevents deficiency of linoleic and alpha‑linolenic acids in patients receiving long‑term lipid‑free intravenous therapy. Energy source for patients unable to receive enteral nutrition: provides readily oxidizable medium‑chain triglycerides to meet metabolic demands during critical illness.

Lipofundin MCT/LCT may be associated with several adverse reactions following intravenous administration.

Common Side Effects: - Hypertriglyceridemia: elevated serum triglyceride levels. - Fever or chills: transient temperature rise during infusion. - Infusion site reactions: erythema, pain or swelling at the catheter site. - Nausea or vomiting: gastrointestinal discomfort during or after infusion.

Serious or Rare Side Effects: - Fat overload syndrome: severe hyperlipidemia leading to organ dysfunction. - Anaphylactic reaction: acute allergic response requiring emergency treatment. - Pulmonary embolism: lipid emboli causing respiratory compromise. - Thrombocytopenia: marked decrease in platelet count.

When using Lipofundin MCT/LCT, clinicians should observe specific precautions to minimize risks and ensure safe administration.

- Monitor triglyceride levels: check serum triglycerides regularly to avoid hypertriglyceridemia. - Assess lipid tolerance: discontinue if severe infusion reactions or intolerance occur. - Use aseptic technique: maintain sterility of the infusion set to prevent contamination. - Adjust in hepatic impairment: monitor liver function tests and modify infusion rate as needed. - Avoid in known soy or egg phospholipid allergy: contraindicated in patients with hypersensitivity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lipofundin MCT/LCT can interact with other medications, affecting lipid metabolism or increasing infusion‑related risks.

Major Interactions (Avoid): - Concurrent lipid emulsions: combined use may cause fat overload syndrome. - Propofol infusion: both provide lipid load, raising risk of hypertriglyceridemia. - High‑dose corticosteroids: may exacerbate serum triglyceride elevation.

Moderate Interactions (Monitor Closely): - Heparin therapy: can alter triglyceride clearance, requiring monitoring. - Diuretics: may affect electrolyte balance during lipid infusion. - Hepatotoxic antibiotics: monitor liver enzymes when co‑administered.